Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Tablets × Plasma cell × Clear all

Phase

Status

Withdrawn 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3 Plasma cell 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Dermatologic 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 121 Lenalidomide 85 daratumumab 56 Bortezomib 53 carfilzomib 40 pomalidomide 36 Calcium Dobesilate 34 Cyclophosphamide 30 isatuximab 20 belantamab mafodotin 18 Melphalan 15 Biopsy 15 Specimen Handling 14 ixazomib 12 fludarabine 12 dexamethasone acetate 12 dexamethasone 21-phosphate 12 Magnetic Resonance Spectroscopy 12 auricularum 11 selinexor 10 iberdomide 9 nirogacestat 8 elotuzumab 8 fludarabine phosphate 7 talquetamab 6 Whole-Body Irradiation 6 Thalidomide 6 Etoposide 6 Doxorubicin 6 trametinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡